Skip to main content

Security report for ucbchina.com

优时比贸易（上海）有限公司 · Healthcare · China

Medium risk. 5 critical or high findings in Email security, Security headers and 2 other checks.

Security score

70/100

Risk levelMedium

0–100, higher is better. How it is calculated

UCB China operates as the Chinese branch of the global biopharmaceutical company UCB S.A., focusing on innovative biologic treatments for rare diseases such as generalized myasthenia gravis. The website serves patients, healthcare professionals, and job seekers by providing detailed product information, corporate news, and recruitment opportunities. The company positions itself as a leader in precision medicine for rare neuromuscular diseases in China, leveraging global innovation and local expertise. Technically, the website is built on Drupal CMS with modern JavaScript usage and integrates Siteimprove Analytics for performance and user behavior tracking. The site is mobile-optimized, accessible, and SEO-friendly, reflecting a mature digital infrastructure. However, some security headers are not explicitly present, and no public security or incident response policies are published. From a security perspective, the site enforces HTTPS and cookie consent mechanisms, ensuring basic user privacy and data protection compliance. No critical vulnerabilities or suspicious content were detected. The WHOIS data aligns well with the business claims, indicating a legitimate and consistent domain registration. Overall, the website demonstrates a solid security posture with room for improvement in transparency and advanced security controls. The risk assessment is low, with no signs of malicious activity or content safety concerns. Strategic recommendations include enhancing security headers, publishing a vulnerability disclosure policy, and improving privacy policy comprehensiveness to align with GDPR and other regulations.

Scanned

NIS2 and GDPR posture

GDPR outside view
53/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

5 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  3. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Policy found

      GDPR requires clear information about cookie usage

      What to do: Add a dedicated cookie policy explaining cookie usage and purposes

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  4. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching ucbchina.com

This scan found 22 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
67
Security headers
65
Email security
60
DNS health
75
Network security
100
GDPR outside view
53
Average
70

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

UCB China is positioned as a medium-sized healthcare entity specializing in innovative biologics for rare diseases, particularly neuromuscular disorders. Its competitive advantage lies in being the first to market with a dual-subtype FcRn antagonist for generalized myasthenia gravis in China. The business model focuses on pharmaceutical R&D, regulatory approvals, and market penetration through patient and healthcare professional engagement. Revenue streams likely include drug sales and partnerships. The target customers are patients with rare diseases, healthcare providers, and potential employees. The company has a strong partnership ecosystem with global UCB and local healthcare institutions. Growth indicators include recent drug approvals and expanding patient support programs. The website reflects a professional and consistent brand image supporting these strategic goals.

Security posture

The website exhibits a mature security posture with HTTPS enforced and cookie consent implemented. However, explicit security headers such as Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options are not detected, which could enhance protection against common web attacks. No incident response or security contact information is published, limiting transparency and readiness perception. No vulnerabilities or exposed sensitive data were found in the HTML content. The absence of a vulnerability disclosure policy or security.txt file is a gap. Overall, the site is secure for general users but could improve in advanced security practices and compliance documentation.

Recommendations

  1. Implement and publish explicit security headers including Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options.
  2. Develop and make publicly available a security policy and incident response contact information.
  3. Create and host a vulnerability disclosure policy or security.txt file to encourage responsible reporting.
  4. Enhance the privacy policy to be more comprehensive and explicitly address GDPR compliance.
  5. Consider adding direct company contact emails and phone numbers for improved user trust and support.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
优时比贸易（上海）有限公司
Description
优时比中国官网，介绍创新生物制药产品，重点推广罗泽利昔珠单抗注射液（优迪革®），治疗全身型重症肌无力，提供企业信息、患者支持、招聘信息及联系方式。
Key services
生物制剂研发, 罕见病治疗方案, 患者支持, 招聘与人才培养
Content quality
good
Branding
consistent

Technology

Stack
JavaScript, Drupal CMS, Siteimprove Analytics
Frameworks
Drupal
Performance
moderate
Mobile
good
Accessibility
good
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent implemented
  • No exposed sensitive data in HTML

Analytics and tracking

Services
Siteimprove Analytics
Tracking level
moderate
Privacy practices
basic

Advertising

Tracking pixels
Siteimprove Analytics
Marketing tools
Siteimprove Analytics
Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is professionally designed and well-structured.
  2. Content is primarily in Chinese with some English terms for medical products.
  3. Focus on pharmaceutical product promotion and corporate information.
  4. No signs of phishing, malware, or suspicious content.
  5. Social media presence is linked and active.
  6. No explicit security or incident response policies published.
  7. Cookie consent is implemented but privacy policy is basic.
  8. No visible email addresses or phone numbers on homepage; contact via form only.
Technical notes

Notes

The website is built on Drupal CMS, leveraging JavaScript and integrates Siteimprove Analytics for monitoring. The site is mobile-optimized and accessible, with good SEO practices including canonical links and meta viewport tags. Performance is moderate, with asynchronous loading of analytics scripts. The technical stack is modern but could benefit from additional security headers and enhanced privacy controls. No hosting provider was explicitly identified from the HTML content. The site structure is clear with well-organized navigation and content sections. Overall, the technical implementation supports a professional and user-friendly experience.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with ucbchina.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review ucbchina.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.